Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in PAH and CTEPH (RIVERII)
NCT04954742Phase 4Terminated
- Sponsor
- Heidelberg University
- Start
- Apr 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of riociguat in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Heidelberg University. Primary endpoints: Right Ventricular Area at 24 weeks and Right Atrial Area at 24 weeks. Started Apr 2022; status: terminated.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT04954742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954742.